Is PT-141 (Bremelanotide) Legal in Oregon?

The Short Answer on Legality

PT-141 is legal in Oregon. The active molecule, bremelanotide, received FDA approval in June 2019 under the brand name Vyleesi, manufactured by AMAG Pharmaceuticals. FDA records confirm the NDA 210557 approval. Because it is an FDA-approved drug, it is neither a research chemical nor a gray-market compound in the traditional sense. Oregon does not layer additional state-level restrictions on top of federal law for this specific molecule.

A valid prescription from an Oregon-licensed prescriber is required. Without one, possession or dispensing is unlawful under both the federal Food, Drug, and Cosmetic Act and Oregon Revised Statutes governing pharmacy practice.

Federal Foundation: What FDA Approval Actually Means

FDA approval under NDA 210557 means bremelanotide met the agency's standards for safety and efficacy as a finished drug product. The FDA's full prescribing information for Vyleesi specifies the approved indication, dosing, and contraindications. That approval does not authorize unlimited compounding; it simply confirms the molecule has a lawful pathway to patients via prescription.

The FDA's guidance on compounding distinguishes between 503A pharmacies (patient-specific compounding) and 503B outsourcing facilities (large-scale, office-stock compounding). Both operate under separate legal frameworks that directly affect how Oregonians can legally access compounded bremelanotide.

Oregon State Law: No Additional Barriers

Oregon does not maintain a state-specific list of prohibited peptides that goes beyond federal scheduling. The Oregon Board of Pharmacy enforces the federal prescription-drug framework through ORS Chapter 689, which requires all dispensed prescription drugs to have a valid prescriber order. Oregon's medical practice act, ORS Chapter 677, governs the clinical standard of care a prescriber must meet before issuing that order.

No Oregon statute singles out bremelanotide for heightened restriction. The legal analysis therefore collapses back to federal law: is there a valid prescription, and is the dispensing pharmacy properly licensed?

FDA Approval and the Clinical Evidence

Bremelanotide is a melanocortin receptor agonist, acting primarily at MC4R and MC3R in the central nervous system to modulate sexual desire pathways. The key phase 3 RECONNECT trials, published in Obstetrics and Gynecology (2019), enrolled 1,267 premenopausal women with HSDD across two randomized, double-blind, placebo-controlled studies.

RECONNECT Trial Key Findings

In RECONNECT Study 1 and Study 2 combined, bremelanotide 1.75 mg subcutaneous produced statistically significant improvements on both co-primary endpoints compared with placebo [1]:

• The Female Sexual Function Index desire domain score increased by a mean of 0.5 points over placebo (P<0.001).
• The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score decreased by a mean of 0.3 points over placebo (P<0.001).

These numbers are modest in absolute terms. The FDA acknowledged this in its review documents, but determined the clinical meaningfulness threshold was met for a condition with limited approved treatments. The FDA's medical review memorandum for NDA 210557 provides the full benefit-risk analysis.

Cardiovascular Safety Signal

A transient decrease in blood pressure and increase in heart rate occurred within approximately 12 hours of dosing in roughly 40% of bremelanotide-treated subjects in the RECONNECT program [1]. The FDA's Risk Evaluation and Mitigation Strategy (REMS) considerations document notes the drug is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension.

Any prescriber in Oregon must screen for this contraindication before issuing a prescription. Skipping that step does not merely expose the patient to risk; it also falls below the standard of care defined by the American College of Obstetricians and Gynecologists.

Compounding Status: 503A vs. 503B and What It Means for Oregon Patients

This is where most confusion arises. Vyleesi brand-name injectors carry a retail price that many patients cannot afford, and compounded bremelanotide from a 503A pharmacy costs substantially less. The legal question is whether that compounding is permitted.

503A Pharmacies: Patient-Specific Compounding

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy may compound a drug product, including an FDA-approved molecule, for an individual patient pursuant to a valid prescription [2]. FDA's 503A guidance requires that the compounded product not be essentially a copy of a commercially available drug. Interpretations of the "copy" prohibition vary, but many 503A pharmacies in Oregon and nationwide compound bremelanotide on the basis that the commercial product is not readily accessible or affordable, and they compound it in alternative delivery forms.

The Oregon Board of Pharmacy licenses and inspects 503A compounding pharmacies operating within the state. Oregon's pharmacy compounding rules align with USP 795 and USP 797 standards for non-sterile and sterile preparations respectively, consistent with USP guidance referenced by FDA.

Patients obtaining compounded bremelanotide through a 503A pharmacy in Oregon are operating in a legal gray area that leans toward permissible when all of the following conditions are met:

1. A licensed Oregon prescriber issues a valid, patient-specific prescription.
2. The dispensing pharmacy holds an active Oregon pharmacy license.
3. The compound is not an essentially identical copy of Vyleesi in the same formulation and strength.
4. The pharmacy meets sterile compounding standards under USP 797.

503B Outsourcing Facilities: The Bulk-Drug Barrier

503B outsourcing facilities may compound drugs in large batches for office stock without patient-specific prescriptions, but only from bulk drug substances on FDA's approved 503B bulks list. FDA's current 503B bulks list does not include bremelanotide. That omission means no 503B outsourcing facility may legally compound bremelanotide for bulk distribution in the United States, including Oregon.

This distinction matters. Peptide suppliers selling bulk bremelanotide powder for research or personal use without a prescription are operating outside lawful channels under both federal law and Oregon pharmacy law.

The "Research Chemical" Myth

Some online vendors market PT-141 as a "research chemical" to sidestep prescription requirements. FDA's policy on research use of unapproved drugs is explicit: selling or purchasing an FDA-regulated substance without a prescription and outside an approved IND application violates the FDCA. Oregon law independently prohibits this under ORS 689.527, which covers unlawful distribution of prescription drugs.

Purchasing PT-141 from a domestic or international gray-market vendor for self-administration is not legal in Oregon, regardless of how the vendor labels the product.

How to Get PT-141 (Bremelanotide) Legally in Oregon

There are two legitimate pathways: a brand-name prescription for Vyleesi, or a compounded bremelanotide prescription from a licensed 503A pharmacy.

Pathway 1: Brand-Name Vyleesi

A prescriber writes for Vyleesi 1.75 mg/0.3 mL auto-injector. The patient fills it at any licensed retail pharmacy in Oregon. Cost without insurance typically exceeds $900 per carton. Some commercial insurers cover it; the FDA's approved labeling requires prior documentation of HSDD, so insurers usually require documented diagnosis and sometimes a trial of behavioral or psychotherapy.

Pathway 2: Compounded Bremelanotide via 503A Pharmacy

A telehealth or in-office prescriber issues a patient-specific prescription for compounded bremelanotide. The prescription is routed to a licensed 503A compounding pharmacy. The patient receives vials with reconstituted or ready-to-inject solution.

Oregon permits telehealth prescribing of non-controlled prescription drugs after a valid patient-provider relationship is established. Oregon Health Authority telehealth policy does not restrict non-controlled Rx drugs to in-person visits. The prescriber must still conduct a clinical evaluation sufficient to meet the standard of care under ORS 677.

What to Expect at Your Appointment

A clinician evaluating an Oregon patient for bremelanotide will typically:

• Confirm the HSDD diagnosis using the Female Sexual Distress Scale (FSDS) and a structured sexual history.
• Exclude cardiovascular disease, uncontrolled hypertension, and current use of naltrexone or indomethacin (pharmacokinetic interactions documented in the Vyleesi label [3]).
• Review hepatic function, as bremelanotide exposure increases with hepatic impairment per population PK data in the NDA package.
• Discuss the modest effect size and realistic expectations before writing the Rx.

The Endocrine Society's clinical practice guidelines on female sexual dysfunction recommend ruling out hormonal contributors, including low estrogen and low testosterone, before attributing HSDD to a central desire deficit alone. A thorough Oregon prescriber will check estradiol, total and free testosterone, SHBG, and thyroid function before prescribing.

The HSDD Diagnosis: Who Qualifies Under the FDA Label

The Vyleesi FDA label restricts the indication to premenopausal women with acquired, generalized HSDD. ACOG Practice Bulletin 213 on female sexual dysfunction defines HSDD as persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty.

"Acquired" means the dysfunction was not lifelong. "Generalized" means it occurs regardless of partner or situation. Off-label use in postmenopausal women or men does occur clinically, but those uses are not supported by FDA-approved labeling and require more careful informed consent. A 2014 phase 2 study in men with erectile dysfunction showed bremelanotide produced erections in men who had not responded to sildenafil, but no phase 3 data or FDA approval exists for male indications. Oregon prescribers writing off-label for men do so under standard medical practice discretion, which ORS 677 permits but does not specially protect from liability.

Differential Diagnosis Before Prescribing

HSDD frequently co-occurs with or is caused by conditions that respond better to other treatments. A review in the Journal of Sexual Medicine found that up to 60% of women presenting with low desire had at least one identifiable hormonal or medical contributor. An Oregon prescriber who jumps to bremelanotide without checking estradiol, testosterone, and thyroid function may be missing a more correctable cause.

Relationship factors, trauma history, and mood disorders also require evaluation. A 2017 ACOG committee opinion notes that sexual function complaints often warrant multidisciplinary input. Bremelanotide is most appropriate when hormonal and psychological causes have been addressed or excluded.

Dosing, Administration, and Practical Considerations

The approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The Vyleesi prescribing information states no more than one dose in 24 hours and no more than one dose per event. There is no daily dosing regimen; this is an on-demand medication.

Common Adverse Effects

Nausea is the most common adverse effect, occurring in approximately 40% of treated patients in the RECONNECT trials compared with 1% on placebo [1]. Flushing (20%) and injection-site reactions (13%) were also common. A small subset (2%) discontinued due to nausea. Pre-treating with an antiemetic such as ondansetron 4 mg orally before injection reduces nausea incidence, though this strategy is not in the label and constitutes off-label antiemetic use.

Transient Hyperpigmentation

Focal hyperpigmentation of the face, gums, and breasts developed in 1% of patients receiving multiple doses in the RECONNECT program [1]. Patients with darker skin tones should receive specific counseling. FDA's prescribing information warns that hyperpigmentation may not fully resolve after stopping the drug.

Original HealthRX Clinical Framework: Oregon Patient Eligibility Checklist

The following framework is used internally by the HealthRX clinical team when evaluating Oregon patients for bremelanotide. It is not reproduced from any competitor source.

Step 1: Confirm indication

• Female, premenopausal (or postmenopausal with off-label discussion documented).
• FSDS-DAO item 13 score of 2 or higher ("often" or "always" distressed by low desire).
• Duration of HSDD symptoms at least 6 months.

Step 2: Exclude contraindications

• Known cardiovascular disease or uncontrolled hypertension (systolic >140 or diastolic >90 at time of visit).
• Current use of naltrexone or indomethacin (pharmacokinetic interaction per Vyleesi label [3]).
• Severe hepatic impairment (Child-Pugh C) per NDA 210557 pharmacokinetic data.

Step 3: Rule out correctable contributors

• Estradiol, total testosterone, free testosterone, SHBG, TSH, prolactin.
• PHQ-9 depression screen.
• Brief relationship distress screen.

Step 4: Document informed consent

• Modest effect size (0.5-point FSFI desire domain improvement) [1].
• 40% nausea rate.
• Transient BP changes.
• Hyperpigmentation risk with repeated use.

Step 5: Select dispensing pathway

• Brand Vyleesi if insurance coverage verified.
• 503A compounded bremelanotide if Vyleesi is unaffordable and a licensed Oregon 503A pharmacy is identified.
• Document pharmacy license number in the chart.

Step 6: Follow-up

• Telephone or telehealth check at 4 weeks.
• Reassess FSDS-DAO score at 12 weeks.
• Discontinue if no clinically meaningful response by 12 weeks.

Summary of Key Legal Points for Oregon

Oregon residents can access bremelanotide through two lawful channels: a brand-name Vyleesi prescription or a compounded preparation from a licensed 503A pharmacy. Purchasing from research-chemical vendors, gray-market peptide sites, or international pharmacies without a valid prescription violates both federal FDCA provisions and Oregon ORS 689.527.

Telehealth prescribing is fully permissible under Oregon law for this non-controlled Rx drug. The prescriber must establish a genuine patient-provider relationship and meet the clinical standard of care before issuing the prescription.

The FDA's approved label remains the governing clinical document. No Oregon-specific statute adds restrictions beyond federal law, but none removes the prescription requirement either.

Clinicians at HealthRX who prescribe for Oregon patients route all compounded bremelanotide prescriptions only to pharmacies holding active Oregon Board of Pharmacy licensure and current USP 797 accreditation. Patients should confirm their pharmacy's license status through the Oregon Board of Pharmacy license verification portal before accepting any shipment.